{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:37:40Z","timestamp":1786977460283,"version":"build-2736575974"},"reference-count":43,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>\n                    Older adults with cirrhosis commonly experience chronic noncancer pain managed with chronic opioid therapy. Current guidelines recommend opioid deprescribing for high\u2010risk populations, including in cirrhosis, but data on tapering and discontinuation are scarce. We described opioid discontinuation rates and identified predictors of tapering or discontinuation. This retrospective cohort study of Medicare fee\u2010for\u2010service beneficiaries (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u2009800,763) \u2265\u200965\u2009years with continuous opioid use for \u2265\u200990\u2009days. The primary outcome was opioid discontinuation (i.e., a gap in refills &gt;\u200930\u2009days). The secondary outcome included opioid tapering (i.e., a 35% decrease in average daily morphine milligram equivalents; [yes\/no]). The primary exposure was diagnosed cirrhosis severity (i.e., none, compensated, decompensated). We estimated discontinuation rates using the Kaplan\u2013Meier method, time to opioid discontinuation using proportional hazards regression, and predictors of tapering with logistic regression. After 1 year, 37% (95% CI\u2009=\u200937\u201337%) of individuals without cirrhosis discontinued opioids, similar to those with compensated (36% (34\u201337%)) and decompensated (37% (35\u201339%)) cirrhosis. Age did not modify the adjusted association between cirrhosis status and discontinuation (Wald\n                    <jats:italic>\u03c7<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    (4)\u2009=\u20097.72,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.10) but calendar year (pre\/post COVID\u201019) did (Wald\n                    <jats:italic>\u03c7<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    (1)\u2009=\u200926.57,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). This finding indicated higher deprescribing rates prior to the pandemic, especially for those without cirrhosis (HR, 1.32; 95% CI, 1.31\u20131.33) compared with those with cirrhosis (HR, 1.13; 95% CI, 1.06\u20131.20). Non\u2010opioid analgesic use, fall history, and frailty significantly increased the odds of tapering. In conclusion, these findings may reflect a lack of safe analgesic alternatives or higher pain burden in cirrhosis.\n                  <\/jats:p>","DOI":"10.1002\/cpt.70223","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:06:11Z","timestamp":1770105971000},"page":"1503-1513","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Opioid Deprescribing Rates and Predictors Among Medicare Enrollees With Cirrhosis and Chronic Pain: Retrospective Cohort Study"],"prefix":"10.1002","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3836-2440","authenticated-orcid":false,"given":"Kevin T.","family":"Pritchard","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9792-2807","authenticated-orcid":false,"given":"Qiaoxi","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4564-3715","authenticated-orcid":false,"given":"Kueiyu Joshua","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital Harvard Medical School  Boston Massachusetts USA"},{"name":"Department of Medicine, Massachusetts General Hospital Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8062-9081","authenticated-orcid":false,"given":"Tracey","family":"Simon","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"e_1_2_13_1_1","unstructured":"Zelaya C.E. Dahlhamer J.M. Lucas J.W.&Connor E.M.Chronic pain and high\u2010impact chronic pain among US adults 2019(2020). NCHS Data Brief No 390. National Center for Health Statistics."},{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269216318807051"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2012.01476.x"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.10.029"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261377"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.10.021"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15639"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.40612"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32378"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1694"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-052057"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-06155-9"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glaa038"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7103a1"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1464"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101277"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32598"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/amiajnl-2013-001856"},{"key":"e_1_2_13_19_1","unstructured":"Chronic Conditions Warehouse.Medicare Administrative Data User Guide Version 3.9<https:\/\/www2.ccwdata.org\/documents\/10280\/19002246\/ccw\u2010medicare\u2010data\u2010user\u2010guide.pdf>. Accessed February 2024."},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2021.01.086"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-06402-z"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.16271"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109392"},{"key":"e_1_2_13_24_1","unstructured":"U.S. Department of Agriculture.Measuring Rurality: Rural\u2010Urban Continuum Codes<https:\/\/www.ers.usda.gov\/data\u2010products\/rural\u2010urban\u2010continuum\u2010codes\/documentation\/>. Accessed July 26 2022."},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glx229"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.10.004"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.9679"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.7326\/M23-3067"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3290"},{"key":"e_1_2_13_30_1","first-page":"49661","article-title":"Schedules of controlled substances: rescheduling of hydrocodone combination products from schedule III to schedule II. Final rule","volume":"79","author":"Drug Enforcement Administration, Department of Justice","year":"2014","journal-title":"Fed. Regist."},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.7326\/M18-1243"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.6989"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.15332"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/0033354919892638"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029944"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.1342"},{"key":"e_1_2_13_37_1","doi-asserted-by":"crossref","unstructured":"Chou R. Hartung D.&Turner J.Opioid treatments for chronic pain comparative effectiveness review no. 229(2020). Agency for Healthcare Research and Quality.","DOI":"10.23970\/AHRQEPCCER229"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14680"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/AAP.0000000000000022"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2018.12.007"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-022-00953-y"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.26523"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0298887"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70223","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.70223","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T03:28:39Z","timestamp":1778297319000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.70223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/cpt.70223"],"URL":"https:\/\/doi.org\/10.1002\/cpt.70223","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"2025-06-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}